Speak to your healthcare provider before making any of these changes
2 CKD confirmatory secondary endpoints Significant 18% RRR of MACE with Ozempic 2 For adults with T2D and CKD, for a confirmatory secondary endpoint: Time to first occurrence of MACE (CV death, nonfatal MI, or nonfatal stroke) vs placebo when both were added to standard of care 1,2 Time to first MACE 1-3,w-z 1-3,w-z w Cumulative incidence estimates are based on time from randomization to first EAC-confirmed MACE with non-CV death modelled as a competing risk using the Aalen-Johnson estimator
Retatrutide does not directly burn fat in the same way a stimulant might increase calorie expenditure
Follow-up labs at 6 to 8 weeks assess initial response
After prolonged cessation, your doctor may recommend re-titrating the dose to minimise gastrointestinal side effects
If a drug can target it, it is instead a matter of biology